Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Abstract Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of gasdermin E (GSDME) and release of HMGB1, markers of pyroptotic cell death. GSDME-deficient melanoma showed defective HMGB1 release, reduced tumor-associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth after drug removal. Importantly, BRAFi + MEKi–resistant disease lacked pyroptosis markers and showed decreased intratumoral T-cell infiltration but was sensitive to pyroptosis-inducing chemotherapy. These data implicate BRAFi + MEKi–induced pyroptosis in antitumor immune responses and highlight new therapeutic strategies for resistant melanoma. Significance: Targeted inhibitors and immune checkpoint agents have advanced the care of patients with melanoma; however, detailed knowledge of the intersection between these two research areas is lacking. We describe a molecular mechanism of targeted inhibitor regulation of an immune-stimulatory form of cell death and provide a proof-of-principle salvage therapy concept for inhibitor-resistant melanoma. See related commentary by Smalley, p. 176. This article is highlighted in the In This Issue feature, p. 161
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“induction of ICD (Box 1) (Erkes et al., 2020; Wang et al., 2020a)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Erkes et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedGSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 3×
“We confirmed the ability of etoposide and also tested doxorubicin, a known chemotherapeutic inducer of pyroptosis, for ability to cause GSDME cleavage in CRT cell lines (31,32,34).”
BackgroundSelf-citationToll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundRelease of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundClassification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationInflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · cited 1×
“It has recently been shown that the intrinsic apoptotic pathway intersects with a distinct form of cell death termed pyroptosis that is gasderminmediated and involves pore-based release of immune stimulatory factors (28-31).”
BackgroundChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 1×
“This pore formation causes the release of immune stimulants, including HMGB1, which are able to induce dendritic cell (DC) activation and, in turn, propagate antitumor T-cell activity (32, 33, 35).”
Background
Cited by
Items 401–500 of 520
Dong, O., Limin, L., Li-feng, L., & Zhao, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1323400/v1
Data from Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
El-Kenawi, A., Berglund, A., Estrella, V. C., Zhang, Y., Liu, M., Putney, R. M., Yoder, S., Johnson, J., Brown, J. S., & Gatenby, R. A. (2023) · doi:10.1158/0008-5472.c.6514344.v1
Rossman, P., Zabka, T. S., Ruple, A., Tuerck, D., Ramos, J. A., Liu, L., Mohallem, R., Merchant, M. A., Franco, J., Fulkerson, C. M., et al. (2023) · doi:10.1158/1535-7163.c.6543510
Rossman, P., Zabka, T. S., Ruple, A., Tuerck, D., Ramos, J. A., Liu, L., Mohallem, R., Merchant, M. A., Franco, J., Fulkerson, C. M., et al. (2023) · doi:10.1158/1535-7163.22522875
Phadke, M. S., Chen, Z., Li, J., Mohamed, E. T., Davies, M. A., Smalley, I., Duckett, D. R., Palve, V. C., Czerniecki, B. J., Forsyth, P. A., et al. (2023) · doi:10.1158/2326-6066.c.6550279
Lelliott, E. J., Mangiola, S., Ramsbottom, K. M., Zethoven, M., Lim, L., Lau, P. K. H., Oliver, A. J., Martelotto, L. G., Kirby, L., Martin, C., et al. (2023) · doi:10.1158/2326-6066.c.6550431
Data from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Ren, Y., Feng, M., Hao, X., Liu, X., Li, J., Li, P., Gao, J., Qi, Q., Du, L., Wang, C., et al. (2023) · doi:10.1158/0008-5472.c.6487386.v2
Song, M., Zhu, Z., Geng, Q., Chen, B., & Cao, G. (2023) · Research Square · doi:10.21203/rs.3.rs-2832419/v1
A pyroptosis score-based model for prognosis prediction of esophageal squamous cell carcinomaPreprint
Wang, J., Meng, J., Sun, F., Tian, X., Luo, J., & Ni, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2933998/v1
Song, M., Zhu, Z., Geng, Q., Chen, B., & Cao, G. (2023) · Research Square · doi:10.21203/rs.3.rs-2956941/v1
Pyroptosis-related genes expression and nomogram predict overall survival of gastric cancerPreprint
Wang, S., Li, X.-C., Zhu, J.-R., Ran, J.-T., & Guan, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-2993160/v1
Checkpoint on I–O resistance: lessons learnt & future perspectives
Stewart, R. A., Miller, M. L., Camelo, A., & Barrett, J. C. (2023) · Immuno Oncology Insights · doi:10.18609/ioi.2023.023
Innovative Pharmacometric Approaches to Inform Drug Development and Clinical Use
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4503-4
ERK-MyD88 interaction inhibition : a novel therapeutic approach in resistant melanoma
Frem, R. (2023) · theses.fr (ABES) · doi:10.70675/539b64edz229cz4d72z911ez81df56ecd401
Li, Z., Xia, Z., Yu, Y., Cai, L., Jian, W., Wang, T., Xue, W., Wang, X., Wang, B., Zhang, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21213414
Yu, H., Gong, M., Qi, J., Zhao, C., Niu, W., Sun, S., Li, S., Hong, B., Qian, J., Wang, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488455
Chen, X., Yang, M., Wang, L., Wang, Y., Tu, J., Zhou, X., & Yuan, X. (2023) · Figshare · doi:10.6084/m9.figshare.22775926
Li, Z., Xia, Z., Yu, Y., Cai, L., Jian, W., Wang, T., Xue, W., Wang, X., Wang, B., Zhang, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21213426
Yu, H., Gong, M., Qi, J., Zhao, C., Niu, W., Sun, S., Li, S., Hong, B., Qian, J., Wang, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488452
Li, Z., Xia, Z., Yu, Y., Cai, L., Jian, W., Wang, T., Xue, W., Wang, X., Wang, B., Zhang, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21213417
Yu, H., Gong, M., Qi, J., Zhao, C., Niu, W., Sun, S., Li, S., Hong, B., Qian, J., Wang, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488458
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Figshare · doi:10.6084/m9.figshare.14759595
Li, Z., Xia, Z., Yu, Y., Cai, L., Jian, W., Wang, T., Xue, W., Wang, X., Wang, B., Zhang, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21213420
Li, Z., Xia, Z., Yu, Y., Cai, L., Jian, W., Wang, T., Xue, W., Wang, X., Wang, B., Zhang, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21213432
Hu, J., Tian, C., Zhao, Y., Guo, Y., & Chen, S. (2022) · Figshare · doi:10.6084/m9.figshare.20315798
Li, Z., Xia, Z., Yu, Y., Cai, L., Jian, W., Wang, T., Xue, W., Wang, X., Wang, B., Zhang, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21213423
Yu, H., Gong, M., Qi, J., Zhao, C., Niu, W., Sun, S., Li, S., Hong, B., Qian, J., Wang, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488449
Di, L., Li, M., Lei, X., Xie, W., Liu, G., Wang, Y., Zhang, W., & Zhu, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-65018-z
“In 2020, Erkes et al. found that BRAF and MEK inhibitors promote T cell infiltration in the immune microenvironment of melanomas through pyroptosis, thereby increasing the sensitivity of the tissue to drug activity and this approach has been widely used in clinical treatment 9 .”
MethodInnate Immune Remodeling Drives Therapy Resistance via Macrophage–NK Cell CrosstalkPreprint
Hsu, C., Lee, K., Chen, J., Donahue, L. R., Lin, J., Kacaj, D., Zhang, Z., & White, A. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.22.666055
Wang, X., Zhao, Z., Liu, L., Cheng, J., & Ba, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.01.673435
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Figshare · doi:10.6084/m9.figshare.14759580
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Figshare · doi:10.6084/m9.figshare.14759586
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568856
Yang, J., Wang, C., Zhang, Y., Cheng, S., Xu, Y., & Wang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24172020
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Figshare · doi:10.6084/m9.figshare.14759589
Chen, X., Yang, M., Wang, L., Wang, Y., Tu, J., Zhou, X., & Yuan, X. (2023) · Figshare · doi:10.6084/m9.figshare.22775923
Li, Z., Xia, Z., Yu, Y., Cai, L., Jian, W., Wang, T., Xue, W., Wang, X., Wang, B., Zhang, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21213411
Chen, X., Yang, M., Wang, L., Wang, Y., Tu, J., Zhou, X., & Yuan, X. (2023) · Figshare · doi:10.6084/m9.figshare.22775917
Yang, Y., Wang, S., Wang, X.-X., Guo, S., Wang, H., Shi, Q., Tian, Y., Wang, H., Zhao, T., Zhang, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674694
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Figshare · doi:10.6084/m9.figshare.14759592
Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25322972
Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S. H., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25322837
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Figshare · doi:10.6084/m9.figshare.14759583
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568850
Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26687040
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568862
Yu, H., Gong, M., Qi, J., Zhao, C., Niu, W., Sun, S., Li, S., Hong, B., Qian, J., Wang, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488443
Sander, C., Rush, E. A., Shi, J., Arantes, L. M. R. B., Tesi, R. J., Ross, M. A., Calderon, M. J., Watkins, S. C., Kirkwood, J. M., Ferris, R. L., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20374584
Yu, H., Gong, M., Qi, J., Zhao, C., Niu, W., Sun, S., Li, S., Hong, B., Qian, J., Wang, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488446
Chen, W., He, Y., Zhou, G., Chen, X., Ye, Y., Zhang, G., & Liu, H. (2024) · Figshare · doi:10.6084/m9.figshare.25010519
Chen, X., Yang, M., Wang, L., Wang, Y., Tu, J., Zhou, X., & Yuan, X. (2023) · Figshare · doi:10.6084/m9.figshare.22775920
Yang, J., Wang, C., Zhang, Y., Cheng, S., Xu, Y., & Wang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24172026
Yu, H., Gong, M., Qi, J., Zhao, C., Niu, W., Sun, S., Li, S., Hong, B., Qian, J., Wang, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488440
Yang, J., Wang, C., Zhang, Y., Cheng, S., Xu, Y., & Wang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24172023
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568853
Yang, Y., Wang, S., Wang, X.-X., Guo, S., Wang, H., Shi, Q., Tian, Y., Wang, H., Zhao, T., Zhang, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674697
Chen, W., He, Y., Zhou, G., Chen, X., Ye, Y., Zhang, G., & Liu, H. (2024) · Figshare · doi:10.6084/m9.figshare.25010344
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568841
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568868
Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S. H., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26687037
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568844
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568865
Yang, Y., Wang, S., Wang, X.-X., Guo, S., Wang, H., Shi, Q., Tian, Y., Wang, H., Zhao, T., Zhang, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25116175
Yang, Y., Wang, S., Wang, X.-X., Guo, S., Wang, H., Shi, Q., Tian, Y., Wang, H., Zhao, T., Zhang, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25116029
Yang, J., Wang, C., Zhang, Y., Cheng, S., Xu, Y., & Wang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24172029
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568838
Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S. H., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26687043
Zhang, L., Chen, C., Chai, D., Li, C., Qiu, Z., Kuang, T., Liu, L., Deng, W., & Wang, W. (2024) · Figshare · doi:10.6084/m9.figshare.26568847
Liu, Y.-G., Jiang, S.-T., Zhang, L., Zheng, H., Zhang, T., Zhang, J.-W., Zhao, H., Sang, X.-T., Xu, Y., & Lu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26603257
Yi, Z., Li, X., Li, T., Chen, Y., Liu, W., Che, J., & Cai, H. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116046
Mahato, M., Mondal, P., & Bhattacharyya, S. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00528-y
トリプルネガティブ乳がんにおけるTGF-βシグナル抑制を介したpolyI : Cの抗腫瘍効果のメカニズム
Tamura, Y. (2021) · Institutional Repositories DataBase (IRDB) · doi:10.15083/0002007132
Wang, Q., & Zhu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1820654
Banerjee, S., & Mukhopadhyay, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40471-9.00001-x
Stem cells and pyroptosis in muscle injury
Sarkar, A., Saha, A., Mandal, I., & Das, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40471-9.00010-0
Xu, X., Liu, Q., Liu, S., Zhang, Y., Yang, M., Xue, J., Sun, P., Liu, J., & Gao, Z. (2026) · Discover Oncology · doi:10.1007/s12672-026-05005-0
“This led us to speculate that antitumor immunity was closely related to pyroptosis in HNSCC. Melanoma lacking GSDME releases HMGB1 under the action of BRAFi + MEKi, lowers T cells and activates dendritic cell infiltration [51].”
HPV16E7-specific affitoxin induces GSDME-mediated pyroptosis via a caspase-3-independent pathway
Li, Y., Jing, X., Liu, J., Feng, S., Wan, K., Xie, Z., Zhang, L., Du, W., & Li, W. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107911
TFAP2A links drug resistance to antitumor immunityPreprint
Mou, H., Yakovishina, V., DeRosa, K. M., Chen, Y., Xiao, M., Dunne, M., Shi, N., Thomas, M., Smith, J. L., Liu, Q., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.08.735861
Bhatt, R., Ong, S., Erkes, D. A., Leung, K. M. X., Kinase, K., Lim, K. Y., Bonfim‐Melo, A., Alghamdi, E., Daignault, S. M., Lim, Y. P., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01808-4
Self-citationHsu, C., Chen, J., Donahue, L. R., Lee, K., Chang, Y.-W., Lin, J., Kacaj, D., White, R. M., Weiss, R. S., Zhang, Z., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-5751
“…possibility is that MAPK pathway inhibition reshapes the tumor-derived cytokine and chemokine milieu, induces tumor cell stress or death, and drives tumor remodeling early during therapy, providing activating cues that promote antigen presentation and chemokine expression in macrophages (7, 50–53).”
PhSAN induces PANoptosis via targeting RNF25-mediated endoplasmic reticulum stress
Kang, J., Jian, Y., Zhang, Y., Li, L., Wang, Z., Liu, T., Lei, Y., Lu, M., Ye, L., Xiang, H., et al. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100353
“For instance, chemoradiotherapy and targeted therapies have been shown to concurrently or sequentially engage both apoptosis and pyroptosis within the same tumor microenvironment (Erkes et al., 2019; Wang et al., 2017; Zhou et al., 2018).”
Dirven, I., Ang, C., Bertels, C., Kortbeek, K., de Haar-Holleman, A., Vollebergh, M. A., Poulikakos, P. I., & Neyns, B. (2026) · Cancer · doi:10.1002/cncr.70569
Sri-ngern-ngam, K., Müller, P., Quatraccioni, A., Zschernack, V., Hamed, M., Surges, R., Schoch, S., Pitsch, J., Becker, A. J., & Cases‐Cunillera, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.10.743180
Yue, H., Zhou, Q., Wang, S., Li, S., Li, J., La, H., & Meng, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176749
“Preclinical studies have shown that BRAF/MEK inhibitors can remodel the tumour immune microenvironment by inducing immunogenic cell death [14], upregulating MHC-I expression [15], reducing MDSC infiltration [16] and releasing heat shock proteins [17,18].”
Zhang, X., Wang, Z., Shi, Y., Li, Q., Chen, S., He, L., Chai, Y., Xu, H., Zhang, Y., Zhao, M., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02426-8
“Further analyses revealed a progressive increase in NPM1 levels in monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), MM, and plasma cell leukemia (PCL), indicating that NPM1 expression in CD138 + cells was correlated with MM progression (Fig.”
(2026) · Pakistan Veterinary Journal · doi:10.29261/pakvetj/2026.199
Westerveld, M. (2020) · The Atrium (University of Guelph)
Interconnected death: crosstalk among ferroptosis, cuproptosis, and pyroptosis in cancer
Liu, Y., Liu, J., Zeng, D., Chen, L., Wei, C., Qiu, X., Fu, L., & Deng, Z. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02799-z
Zhao, Y., Zhu, Y., Zhong, S., Liu, P., Li, W., 毛晓韵, & Xu, X. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.131070
“Pyroptosis induced by BRAF plus MEK inhibitors plays an important role in modulating immune cell populations and overcoming drug resistance in melanoma (21, 22).”
The gasdermin family: from pyroptosis mechanisms to therapeutic targets
Xu, W., Liu, S., Yu, Z., Shi, J., Yang, Y., & Shi, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02867-2
“433 In conclusion, pyroptosis acts as a double-edged sword in tumorigenesis.”
Li, R., Lin, Y., Guo, J., Qian, J., Wu, M., Zhang, Y., Xiao, L., Li, R., & Zhang, X. (2026) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001846
Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structuresPreprint
Yang, X., Li, M., Zhang, J., He, D., Liu, X., Liu, L., Duan, J., Wang, Z., Bai, H., & Wang, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.12.756217
“The reduction in CD3+ T cells was consistent with a previous study reporting that BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis[30].”
Dong), 董. (2022) · China National GeneBank DataBase · doi:10.26036/cnp0002696
Cui, X., Zhang, Q., Hu, J., Li, X., Shu, C., 西仪宣, Zheng, S., ma, S., Li, F., Bai, X., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1970372
Killing with a purpose: harnessing immunological cell death in brain tumors
Young, R. G., Edgerton, A. O., Clouser, K. A., Kutzler, M. A., Haddad, E. K., & Reginato, M. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1973683
Lu, H., Wu, J., Liang, L., Wang, X., & Cai, H. (2022) · doi:10.3389/fimmu.2022.803355.s001
Chen, Y., Liao, Y., Du, Q., Shang, C., Qin, S., Lee, K., Zou, Q., Liu, J., & Yao, S. (2022) · doi:10.3389/fmed.2022.822806.s003
Cai, Y., Li, K., Lin, J., Liang, X., Xu, W., Zhan, Z., Xue, S., Zeng, Y., Chai, P., Mao, Y., et al. (2022) · doi:10.3389/fimmu.2022.910490.s004
Metadata
- Authors
- Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., & Aplin, A. E.
- Affiliations
- Thomas Jefferson University (US)
- Corresponding author
- Alnemri, Emad S.
- Aplin, Andrew E.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-02-01
- Volume
- 10
- Issue
- 2
- Pages
- 254-269
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7007378
- OpenAlex
- W2993434511
- Cited by
- 459
- References
- 67
- Citations by year
- 2026: 38 · 2025: 52 · 2024: 78 · 2023: 84 · 2022: 114 · 2021: 72 · 2020: 21
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (CA196278, CA160495, CA182635, CA207855)
- Dr. Ralph and Marian Falk Medical Research Trust (N/A)
- HHS | National Institutes of Health (AR055398, AR074564)
- U.S. Department of Defense (PC150650)
- American Cancer Society (PF-18-096-01-LIB)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- BRAF inhibitors, MEK inhibitors, pyroptosis, gasdermin E, HMGB1, tumor immune microenvironment, antitumor immunity, T cell infiltration, dendritic cells, drug resistance, salvage therapy, targeted therapy
- MeSH terms
- Pyroptosis, Proof of Concept Study, Immune Checkpoint Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Dendritic Cells, Disease Models, Animal, Female, Humans, Male, Melanoma, Mutation, Skin Neoplasms, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.